Back to top
more

Gamida Cell Ltd. (GMDA)

(Delayed Data from NSDQ)

$7.95 USD

7.95
4,607

+0.20 (2.58%)

Updated May 3, 2019 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why Gamida Cell (GMDA) Looks Ripe for Bottom Fishing

by Zacks Equity Research

Gamida Cell (GMDA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Gamida Cell (GMDA)'s Technical Outlook is Bright After Key Golden Cross

by Zacks Equity Research

Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?

Gamida Cell (GMDA) Surges on FDA Approval for Omisirge

by Zacks Equity Research

Gamida Cell's (GMDA) shares surge as it receives FDA approval for Omisirge, an allogeneic cell therapy for blood cancer patients.

Gamida Cell (GMDA) Upgraded to Buy: Here's Why

by Zacks Equity Research

Gamida Cell (GMDA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Pfizer (PFE) 2nd Ulcerative Colitis Study on Etrasimod Succeeds

by Zacks Equity Research

Pfizer's (PFE) ELEVATE UC 52 is the second phase III study on etrasimod for ulcerative colitis to have met primary and key secondary endpoints.

Has Champions Oncology, Inc. (CSBR) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Champions Oncology, Inc. (CSBR) and Gamida Cell (GMDA) have performed compared to their sector so far this year.

Acadia Healthcare (ACHC) Up 10% in 3 Months: More Room to Run?

by Zacks Equity Research

Solid demand for behavioral healthcare services, multiple growth-related initiatives and a solid cash balance are driving Acadia Healthcare (ACHC).

Mei Pharma (MEIP) to Delay Filing With FDA for Lymphoma Drug

by Zacks Equity Research

Mei Pharma's (MEIP) FDA filing plans for zandelisib for lymphoma indication get derailed after the agency requests more clinical studies. The stock plummets in after-market trading post this news.

Creative Medical (CELZ) Up 82% on Stem Cell Treatment Data

by Zacks Equity Research

Creative Medical Technology (CELZ) reports positive follow-up data from a pilot study evaluating StemSpine, a patented stem cell treatment for chronic lower back pain.

Vertex (VRTX) to Begin Pivotal Study on Kidney Candidate

by Zacks Equity Research

Vertex's (VRTX) pivotal phase III study on VX-147 targeting a broad patient population with proteinuric kidney disease mediated by two mutations in the APOL1 gene (AMKD) is expected to begin later this month.

UnitedHealth Group (UNH) Gains 38% in a Year: More Room to Run?

by Zacks Equity Research

Continued revenue growth, management optimism surrounding the Medicaid business, several contract wins, and solid cash balance continue to drive UnitedHealth Group (UNH).

AstraZeneca's (AZN) Fasenra sBLA for Nasal Polyps Gets CRL

by Zacks Equity Research

The FDA gives CRL to AstraZeneca's (AZN) sBLA for Fasenra for chronic rhinosinusitis with nasal polyps (CRSwNP) for want of additional clinical

AstraZeneca (AZN) Stock Up 27% in a Year: What Lies Ahead?

by Zacks Equity Research

AstraZeneca's (AZN) stock has risen 26.9% in the past year compared with an increase of 22.3% for the industry.

Allogene's (ALLO) CAR T Therapy Gets Fast Track Designation

by Zacks Equity Research

The FDA grants a Fast Track designation to Allogene's (ALLO) early-stage CAR T therapy candidate, ALLO-316, for treating advanced or metastatic clear cell RCC.

Has Paragon 28, Inc. (FNA) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Paragon 28, Inc. (FNA) and Gamida Cell (GMDA) have performed compared to their sector so far this year.

Merck (MRK) Outperforms Industry, What's in Store for 2022?

by Zacks Equity Research

Strong sales of key products like Keytruda and Gardasil, a significant contribution from molnupiravir and positive pipeline/regulatory developments can keep Merck's (MRK) stock afloat in 2022.

Amarin (AMRN) Q4 Earnings Top, Sales Hurt by Vascepa Generics

by Zacks Equity Research

Amarin's (AMRN) Vascepa sales decline amid rising generic competition and COVID-19 related disruptions during the fourth quarter. The company's stock falls on Mar 1, following the earnings release.

Is a Surprise Coming for Gamida (GMDA) This Earnings Season?

by Zacks Equity Research

Gamida (GMDA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Perrigo (PRGO) Q4 Earnings Beat as Cough & Cold Sales Recover

by Zacks Equity Research

Perrigo (PRGO) reports encouraging fourth-quarter 2021 results. Sales of cough/cold products continue the strong rebound during the reported quarter. Stock gains.

Emergent's (EBS) Q4 Earnings & Sales Beat, CDMO View Cut

by Zacks Equity Research

Emergent's (EBS) fourth-quarter 2021 earnings and sales beat estimates. The company lowers its guidance for 2022 CDMO services revenues and adjusted net income.

BioMarin (BMRN) Q4 Earnings Top Estimates, Sales Fall Y/Y

by Zacks Equity Research

Biomarin Pharmaceutical's (BMRN) fourth-quarter earnings and sales beat estimates. Stock declines

Allogene (ALLO) Beats on Q4 Earnings, Resumes Clinical Studies

by Zacks Equity Research

Allogene (ALLO) beats earnings estimates for the fourth quarter. However, the stock declines in after-market trading. All clinical studies have been resumed following the removal of clinical hold last month.

Kinjel Shah headshot

5 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates

by Kinjel Shah

Let us take a look at some drug/biotech stocks, EVLO, GMDA, APLS, MRTX and ITOS, which are poised to beat on fourth-quarter earnings.

Esperion (ESPR) Q4 Earnings Beat, Product Sales Rise 49%

by Zacks Equity Research

Esperion Therapeutics (ESPR) reports solid fourth-quarter results, beating estimates for earnings and sales. Stock surges.

Novavax (NVAX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On Novavax's (NVAX) fourth-quarter earnings call, investor focus is likely to be on the initial sales numbers of the company's COVID-19 vaccine.